Market Overview:
The global mono hepatitis vaccine market is expected to grow at a CAGR of 9.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of hepatitis A and B infections, increasing awareness about preventive measures against these infections, and technological advancements in the field of mono hepatitis vaccines. Based on type, the global mono hepatitis vaccine market is segmented into hepatitis A vaccines and hepatitis B vaccines. Hepatitis A vaccines are further sub-segmented into inactivated virus vaccine and live attenuated virus vaccine. Hepatitis B vaccines are further sub-segmented into recombinant DNA vaccine and plasma derived protein antigenvaccine. In terms of application, the global mono hepatica vaccinemarket is segmentedinto childrenand adults.
Product Definition:
Mono hepatitis vaccine is a vaccine used to prevent infection by the Epstein-Barr virus, which can cause mono (mononucleosis). Mono hepatitis vaccine is given as two injections, six to twelve months apart. It is recommended for people who are at high risk of exposure to the Epstein-Barr virus, such as students in college dormitories and people who work with children.
Hepatitis A Vaccines:
Hepatitis A is an inflammation of liver tissue caused by the hepatitis virus. There are different types of hepatitis viruses, some are more serious than others and can lead to chronic conditions. Hepatitis A can range from a mild illness with just jaundice to a severe illness that requires hospitalization. The most common symptoms include fatigue, nausea, vomiting, loss of appetite along with abdominal pain and diarrhea.
Hepatitis B Vaccines:
Hepatitis B is an inflammation of liver tissue caused by the Hepatitis virus (HBV or HCV). The disease can lead to serious complications such as liver failure and even death. According to the Centers for Disease Control and Prevention, around 1.4 million people in U.
Application Insights:
Based on the application, the global mono hepatitis vaccine market is segmented into children and adult. The children segment held a larger share in 2017 owing to higher prevalence of infection among this population. According to WHO, around 90% of people with chronic liver disease are infected due to consumption of contaminated alcohol or drugs. In addition, increasing number of clinical trials supporting its use in children as well as adults is further expected to drive demand over the forecast period.
The adult segment is expected to witness significant growth during the forecast period due largely unvaccinated population base across various regions coupled with high incidence rate for hepatitis A & B infections among them which washes away their immunity protection leading towards increased risk for diseases recurrence post-treatment. This factor will boost demand for vaccines particularly designed against these viruses amongst adults which may not be effective against pediatric populations thus driving market growth over next few years.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to high awareness levels regarding vaccination programs, presence of well-established healthcare facilities and favorable reimbursement policies for immunization activities. The U.S., which is at the forefront of this region, has witnessed a significant increase in coverage rates since 2013 owing to an aggressive campaign by government agencies as well as non-government organizations (NGOs).
In addition, increasing prevalence of hepatitis A & B and rising demand for improved treatment options are expected to drive regional growth over the forecast period.
Growth Factors:
- Increasing incidence of mono hepatitis across the globe
- Growing awareness about the benefits of vaccination against mono hepatitis
- Rising demand for preventive healthcare measures against mono hepatitis
- Technological advancements in vaccine development and production processes
- Availability of government funding for research and development initiatives on mono hepatitis vaccines
Scope Of The Report
Report Attributes
Report Details
Report Title
Mono Hepatitis Vaccine Market Research Report
By Type
Hepatitis A Vaccines, Hepatitis B Vaccines
By Application
Children, Adult
By Companies
GSK, NCPC, Merck, Bio Kangtai, Dynavax, Hissen, KM Biologics, LG Life Sciences, Serum Institute, Sanofi, Sinovac, Zhejiang Pukang, IMBCA, ChangSheng
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
135
Number of Tables & Figures
95
Customization Available
Yes, the report can be customized as per your need.
Global Mono Hepatitis Vaccine Market Report Segments:
The global Mono Hepatitis Vaccine market is segmented on the basis of:
Types
Hepatitis A Vaccines, Hepatitis B Vaccines
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Children, Adult
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GSK
- NCPC
- Merck
- Bio Kangtai
- Dynavax
- Hissen
- KM Biologics
- LG Life Sciences
- Serum Institute
- Sanofi
- Sinovac
- Zhejiang Pukang
- IMBCA
- ChangSheng
Highlights of The Mono Hepatitis Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Hepatitis A Vaccines
- Hepatitis B Vaccines
- By Application:
- Children
- Adult
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Mono Hepatitis Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
The Mono Hepatitis Vaccine is a vaccine that helps protect people from mono, a liver disease. It is made up of pieces of the virus that cause mono.
Some of the major companies in the mono hepatitis vaccine market are GSK, NCPC, Merck, Bio Kangtai, Dynavax, Hissen, KM Biologics, LG Life Sciences, Serum Institute, Sanofi, Sinovac, Zhejiang Pukang, IMBCA, ChangSheng.
The mono hepatitis vaccine market is expected to grow at a compound annual growth rate of 9.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Mono Hepatitis Vaccine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Mono Hepatitis Vaccine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Mono Hepatitis Vaccine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Mono Hepatitis Vaccine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Mono Hepatitis Vaccine Market Size & Forecast, 2020-2028
4.5.1 Mono Hepatitis Vaccine Market Size and Y-o-Y Growth
4.5.2 Mono Hepatitis Vaccine Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Hepatitis A Vaccines
5.2.2 Hepatitis B Vaccines
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Children
6.2.2 Adult
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Mono Hepatitis Vaccine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Mono Hepatitis Vaccine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Hepatitis A Vaccines
9.6.2 Hepatitis B Vaccines
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Children
9.10.2 Adult
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Hepatitis A Vaccines
10.6.2 Hepatitis B Vaccines
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Children
10.10.2 Adult
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Hepatitis A Vaccines
11.6.2 Hepatitis B Vaccines
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Children
11.10.2 Adult
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Hepatitis A Vaccines
12.6.2 Hepatitis B Vaccines
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Children
12.10.2 Adult
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Hepatitis A Vaccines
13.6.2 Hepatitis B Vaccines
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Children
13.10.2 Adult
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Mono Hepatitis Vaccine Market: Competitive Dashboard
14.2 Global Mono Hepatitis Vaccine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GSK
14.3.2 NCPC
14.3.3 Merck
14.3.4 Bio Kangtai
14.3.5 Dynavax
14.3.6 Hissen
14.3.7 KM Biologics
14.3.8 LG Life Sciences
14.3.9 Serum Institute
14.3.10 Sanofi
14.3.11 Sinovac
14.3.12 Zhejiang Pukang
14.3.13 IMBCA
14.3.14 ChangSheng
